Clorox Shorts Pull Back Sharply Ahead of Monday's Print

CLX arrives at its November 2 earnings release with short sellers cutting positions at an unusual pace, reversing a build that had been one of the more aggressive accumulations seen in the consumer staples sector this autumn.

Short interest dropped 15.7% in a single session on October 29, and is now down 14% on the week to 8.8% of the free float, around 10.8 million shares. That pullback is notable: the previous ORTEX preview, published October 27, documented how positions had surged 30% over the prior month to roughly 12.4 million shares. That build has now partially unwound. The one-month change, at plus 11.6%, still points to a net accumulation since late September, but the direction has reversed sharply in the days immediately before the print. Days to cover of 4.1 confirm the remaining position is still material relative to normal volume.

Borrow conditions remain relaxed. Availability is around 310% of short interest, meaning shares available to lend comfortably outnumber those already borrowed. Cost to borrow is unchanged near 0.5%, a level that has barely shifted in six weeks. The lending market is offering no friction to short sellers in either direction. Options positioning is mildly defensive: the put/call ratio is at 0.92, above its 20-day average of 0.89, but the z-score of 0.53 is nowhere near extreme. Retail attention, measured by Wikipedia page views against the company's own 90-day history, is running at a z-score of 3.3, unusually elevated for a household products name this close to a report.

The analyst community entered this earnings window in a notably negative posture. JP Morgan cut its price target to $83 from $95 on October 19, while Barclays lowered to $80 from $84 and Morgan Stanley trimmed to $87 from $97. Citigroup, TD Cowen, and Wells Fargo all reduced targets in the same two-week window, none upgraded. The consensus target of $96 sits above the current $88 price, but the direction of travel across the Street has been uniformly downward. The stock's EPS momentum factor ranks in the 14th percentile on a 30-day basis, and the 90-day reading is only marginally better at the 18th. The ORTEX short score has eased to 55.9 from 64.6 at the start of the week, consistent with the short-covering visible in the underlying data.

The print will test whether the partial short cover ahead of the release reflects genuine reassessment of the bear case, or simply pre-event risk management in a stock where the fundamental debate, around margin recovery pace and organic volume, remains unresolved.